MDACC Study No:2005-0234 ( NCT No: NCT00383994)
Title:Immunotherapy with NK cell, Rituximab and rhu-GMCSF in Non-myeloablative Allogeneic Stem Cell Transplantation
Principal Investigator:Issa F. Khouri
Treatment Agent:GM-CSF; Rituximab
Study Status:Terminated
Study Description:The goal of this clinical research study is to find out if giving a boost of
natural killer (NK) cells from a donor, combined with Rituxan (rituximab), can
help to control disease in patients who have already received an allogeneic
stem cell transplant. The safety of this treatment will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia; Lymphoma
Phase of Study:N/A
Treatment Agents:GM-CSF
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:5 times during the first year and then annually.
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Issa F. Khouri
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults